Full Press Release Details
BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
Bedminster, NJ (April 18, 2017)
- Matinas BioPharma Holdings, Inc. (NYSE MKT: MTNB), a clinical-stage biopharmaceutical company focused on
developing innovative anti-infectives for orphan indications, announced today that it has appointed Dominick DiPaolo as Senior
Vice President of Quality and Regulatory Compliance.
Mr. DiPaolo has extensive experience in
the pharmaceutical industry, both domestically and internationally. Mr. DiPaolo joins the Matinas team having most recently served
as the Senior Vice President of Quality, Compliance and Regulatory Affairs at Cyalume Technologies, a diversified pharmaceutical
and medical device company.
Roelof Rongen, Chief Executive Officer
of Matinas stated, "We are excited to welcome Dominick to the Matinas executive team. His broad pharmaceutical experience
and expertise in the areas of quality and regulatory compliance will prove to be invaluable as we continue to drive our clinical
development and regulatory strategies forward for our lead programs, MAT2203 and MAT2501, and work to build out our internal formulation
and manufacturing capabilities."
Mr. DiPaolo has previously served as Senior
Vice President of Quality, Compliance and Regulatory Affairs at Tris Pharma, a specialty pharmaceutical company of both branded
and generic products. Prior to his time at Tris Pharma, he served as Vice President of Quality and Regulatory for G&W Laboratories,
a niche pharmaceutical company. Earlier in his career, he held various senior quality positions at Barr Laboratories, Pfizer Inc.,
Novartis, Hoffmann-La Roche and Johnson & Johnson. Mr. DiPaolo is both a Certified Quality Engineer ("CQE") as
well as a Certified Quality Auditor ("CQA") from the American Society for Quality.
"I am thrilled to be joining Matinas
at such an exciting time for the Company. I believe that the Company's proprietary cochleate technology platform has the
potential to provide an innovative and effective solution for both patients and physicians across a number of therapeutic areas,
and I look forward to working with the team to unlock the potential I believe Matinas has for developing safer, more tolerable,
less toxic, and orally bioavailable drugs," commented Mr. DiPaolo.
Mr. DiPaolo earned his B.S. in Biotechnology
and Microbiology from Rutgers University in New Brunswick, New Jersey and completed his graduate course work in Microbiology at
Seton Hall University in South Orange, New Jersey.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical
company focused on developing innovative anti-infectives for orphan indications. The Company's proprietary, disruptive technology
utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic
and orally bioavailable.
The Company's lead anti-infective product
candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective
therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology. For more information, please
visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
Forward Looking Statements: This
release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995,
including those relating to the Company's strategic focus and the future development of its product candidates, including MAT2203
and MAT2501, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the Company's
ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable
terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that
depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that
could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates,"
"intends," "plans," "could," "believes," "estimates" and similar expressions.
These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially
different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity
needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials
of our product candidates; our ability to successfully complete research and further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals;
our ability to maintain and derive benefit from the Qualified Infectious Disease Product (QIDP), Orphan and/or Fast Track designations
for MAT2203 and MAT2501, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited
basis, or at all; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel
or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products;
and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors
are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release.
Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas
BioPharma's product candidates are all in a development stage and are not available for sale or use.
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Source: Matinas BioPharma Holdings, Inc.